NasdaqGS:ENDP

Stock Analysis Report

Executive Summary

Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally.


Snowflake Analysis

Moderate growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has Endo International's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ENDP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.3%

ENDP

-0.5%

US Pharmaceuticals

-1.1%

US Market


1 Year Return

-42.2%

ENDP

6.2%

US Pharmaceuticals

17.9%

US Market

Return vs Industry: ENDP underperformed the US Pharmaceuticals industry which returned 6.2% over the past year.

Return vs Market: ENDP underperformed the US Market which returned 17.9% over the past year.


Shareholder returns

ENDPIndustryMarket
7 Day-1.3%-0.5%-1.1%
30 Day2.5%-1.0%1.4%
90 Day24.1%5.7%6.9%
1 Year-42.2%-42.2%8.9%6.2%20.3%17.9%
3 Year-53.8%-53.8%25.4%16.6%47.8%38.3%
5 Year-92.9%-92.9%29.7%15.7%71.9%53.0%

Price Volatility Vs. Market

How volatile is Endo International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Endo International undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ENDP ($6.07) is trading below our estimate of fair value ($28.46)

Significantly Below Fair Value: ENDP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ENDP is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: ENDP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ENDP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ENDP has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Endo International forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

38.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ENDP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: ENDP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ENDP's is expected to become profitable in the next 3 years.

Revenue vs Market: ENDP's revenue is expected to decline over the next 3 years (-0.2% per year).

High Growth Revenue: ENDP's revenue is forecast to decline over the next 3 years (-0.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ENDP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Endo International performed over the past 5 years?

-16.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ENDP is currently unprofitable.

Growing Profit Margin: ENDP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ENDP is unprofitable, and losses have increased over the past 5 years at a rate of -16.9% per year.

Accelerating Growth: Unable to compare ENDP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ENDP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.4%).


Return on Equity

High ROE: ENDP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Endo International's financial position?


Financial Position Analysis

Short Term Liabilities: ENDP has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ENDP has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ENDP has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ENDP's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: ENDP has a low level of unsold assets or inventory.

Debt Coverage by Assets: ENDP has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable ENDP has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: ENDP is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -1.5% per year.


Next Steps

Dividend

What is Endo International's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.7%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate ENDP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ENDP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ENDP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ENDP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ENDP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Paul Campanelli (57yo)

3.4yrs

Tenure

US$19,970,703

Compensation

Mr. Paul V. Campanelli has been the Chief Executive Officer, President, and Executive Director at Endo International plc since September 23, 2016 and has been its Chairman since November 4, 2019. Mr. Campa ...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD19.97M) is above average for companies of similar size in the US market ($USD3.81M).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Paul Campanelli
Chairman3.4yrsUS$19.97m0.30% $4.1m
Blaise Coleman
Executive VP & CFO3.2yrsUS$2.64m0.049% $668.4k
Terrance Coughlin
Executive VP & COO3.3yrsUS$3.13m0.11% $1.5m
Matthew Maletta
Executive VP & Chief Legal Officer4.8yrsUS$2.55m0.047% $648.5k
Jack Boyle
Senior VP0.4yrsno data0.0072% $98.6k
Laure Park
Senior Vice President of Investor Relations & Corporate Affairs1.5yrsno datano data
Susan Williamson
Senior VP & Chief Compliance Officer1.8yrsno datano data
Mark Bradley
Senior VP of Corporate Development & Treasurer3.2yrsno datano data
Tracy Basso
Chief Human Resources Officer1.1yrsno datano data
Joseph Barbarite
Executive Vice President of Global Quality and Compliance3.3yrsno datano data

3.2yrs

Average Tenure

47yo

Average Age

Experienced Management: ENDP's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Paul Campanelli
Chairman3.4yrsUS$19.97m0.30% $4.1m
Mark Barberio
Independent Director0yrsno datano data
Michael Hyatt
Independent Director6yrsUS$315.00k0.14% $1.9m
Roger Kimmel
Senior Independent Director0.3yrsUS$450.00k0.090% $1.2m
William Montague
Independent Director6yrsUS$320.00k0.041% $563.7k
Shane Cooke
Independent Director5.6yrsUS$325.00k0.036% $498.2k
Nancy Hutson
Independent Director6yrsUS$320.00k0.034% $473.1k

5.8yrs

Average Tenure

70yo

Average Age

Experienced Board: ENDP's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Endo International plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Endo International plc
  • Ticker: ENDP
  • Exchange: NasdaqGS
  • Founded: 1920
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.377b
  • Shares outstanding: 226.78m
  • Website: https://www.endo.com

Number of Employees


Location

  • Endo International plc
  • Minerva House
  • First Floor
  • Dublin
  • Co. Dublin
  • 4
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ENDPNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2000
EO7DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2000
ENDP NBMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJul 2000
0Y5FLSE (London Stock Exchange)YesCommon StockGBUSDJul 2000

Biography

Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. Its U.S. Branded - Specialty & Established Pharmaceuticals segment provides branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain, and orthopedics. This segment offers XIAFLEX to treat adult patients with Dupuytren’s contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL Nasal Spray to treat vitamin B12 deficiency; TESTOPEL for TRT in conditions associated with a deficiency or absence of endogenous testosterone; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; VOLTAREN Gel for the relief of joint pain of osteoarthritis; LIDODERM for the relief of pain; FORTESTA Gel for men suffering from hypogonadism; EDEX to treat erectile dysfunction; and TESTIM for TRT in conditions associated with a deficiency or absence of endogenous testosterone. The company’s U.S. Branded - Sterile Injectables segment offers branded sterile injectable products, such as VASOSTRICT, ADRENALIN, and APLISOL; and generic sterile injectable products. Its U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics, and sprays; and products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and cardiovascular disease markets. The company’s International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women’s health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. The company was founded in 1920 and is headquartered in Dublin, Ireland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 00:34
End of Day Share Price2020/02/21 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.